|Mr. Hugh O'Dowd||Pres, CEO & Director||688.75k||N/A||1965|
|Dr. Eric S. Lander||Director||69.71k||N/A||1957|
|Dr. Yasir B. Al-Wakeel||Chief Financial Officer||529.93k||N/A||1982|
|Dr. Richard Gaynor||Pres of R&D||536.77k||N/A||1950|
|Dr. Edward Fritsch||Founder & CTO||N/A||N/A||N/A|
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Neon Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 8.